SDC1 and plasma cell myeloma: This allows for CD138 to be a viable target for CAR T cell therapy [20-21]. CD138 is more expressed in relapsed and refractory multiple myeloma (RRMM) rather than new cases, making CD138 an important target for anti-MM therapy [22].